Stem definition | Drug id | CAS RN |
---|---|---|
beta-lactamase inhibitors | 5342 | 1174018-99-5 |
Dose | Unit | Route |
---|---|---|
2 | g | P |
Property | Value | Reference |
---|---|---|
S (Water solubility) | 70 mg/mL | Bocci G, Oprea TI, Benet LZ |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
June 16, 2019 | FDA | MSD MERCK CO | |
June 23, 2021 | PMDA | MSD K.K. |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | J01DH56 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D065093 | beta-Lactamase Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Infection caused by Pseudomonas aeruginosa strain resistant to carbapenem antimicrobial drugs | indication | 11218009 | |
Pyelonephritis | indication | 45816000 | DOID:11400 |
Urinary tract infectious disease | indication | 68566005 | |
Infection caused by Escherichia coli strain resistant to carbapenem antimicrobial drugs | indication | 71057007 | |
Infection caused by Serratia spp resistant to carbapenem antimicrobial drugs | indication | 71120004 | |
Intestinal infection due to Pseudomonas | indication | 82930004 | |
Intestinal infection due to E. coli | indication | 111839008 | |
Infectious disease of abdomen | indication | 128070006 | |
Pseudomonas gastrointestinal tract infection | indication | 266078006 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Pseudomonas urinary tract infection | indication | 301013004 | |
Infection caused by Enterococcus spp resistant to carbapenem antimicrobial drugs | indication | 406574007 | |
Gastrointestinal infection caused by Klebsiella aerogenes | indication | 421429008 | |
Infection caused by Klebsiella spp resistant to carbapenem antimicrobial drugs | indication | 721756002 | |
Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs | indication | 840588006 | |
Infection caused by Citrobacter spp resistant to carbapenem antimicrobial drugs | indication | 1137353009 | |
Urinary tract infection caused by Klebsiella | indication | ||
Complicated Genitourinary Tract Infection | indication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 13.53 | acidic |
pKa2 | 9.75 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL | RECARBRIO | MSD MERCK CO | N212819 | July 16, 2019 | RX | POWDER | INTRAVENOUS | 8487093 | Nov. 19, 2029 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI) |
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL | RECARBRIO | MSD MERCK CO | N212819 | July 16, 2019 | RX | POWDER | INTRAVENOUS | 8487093 | Nov. 19, 2029 | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI) |
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL | RECARBRIO | MSD MERCK CO | N212819 | July 16, 2019 | RX | POWDER | INTRAVENOUS | 8487093 | Nov. 19, 2029 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL | RECARBRIO | MSD MERCK CO | N212819 | July 16, 2019 | RX | POWDER | INTRAVENOUS | July 16, 2024 | NEW CHEMICAL ENTITY |
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL | RECARBRIO | MSD MERCK CO | N212819 | July 16, 2019 | RX | POWDER | INTRAVENOUS | July 16, 2029 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-lactamase | Enzyme | INHIBITOR | IC50 | 6.40 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Beta-lactamase | Enzyme | INHIBITOR | IC50 | 6.33 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Beta-lactamase | Enzyme | INHIBITOR | IC50 | 6.64 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Beta-lactamase | Enzyme | INHIBITOR | IC50 | 6.59 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Beta-lactamase | Enzyme | INHIBITOR | IC50 | 6.04 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Beta-lactamase | Enzyme | IC50 | 6.33 | CHEMBL |
ID | Source |
---|---|
Y1MYA2UHFL | UNII |
C4317244 | UMLSCUI |
CHEMBL3301605 | ChEMBL_ID |
CHEMBL3112741 | ChEMBL_ID |
44129647 | PUBCHEM_CID |
DB12377 | DRUGBANK_ID |
D11621 | KEGG_DRUG |
C000633884 | MESH_SUPPLEMENTAL_RECORD_UI |
10852 | IUPHAR_LIGAND_ID |
018062 | NDDF |
789066008 | SNOMEDCT_US |
4039070 | VANDF |
1174020-13-3 | SECONDARY_CAS_RN |
2184137 | RXNORM |
321713 | MMSL |
37333 | MMSL |
d09357 | MMSL |
C568736 | MESH_SUPPLEMENTAL_RECORD_UI |
None